← Eichor
Study identifier: NCT06240299 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Neurofeedback for Nociplastic Pain in Rheumatoid Arthritis (NECTAR)

Condition: Rheumatoid Arthritis · Chronic Widespread Pain  ·  Sponsor: NHS Greater Glasgow and Clyde

PhaseNA
Planned participants16
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

Rheumatoid arthritis is an autoimmune condition, causing inflammation and pain. Yet pain may persist even when inflammation has been treated. This residual pain, called nociplastic pain, has symptoms of a chronic pain condition called fibromyalgia. There are few effective therapies to address this residual pain. Published literature shows that fibromyalgia can be treated by neurofeedback, a noninvasive method that is based on the voluntary modulation of cortical activity. In this pilot study, the investigators want to test the effect of neurofeedback on the fibromyalgia component of pain in rheumatoid arthritis, and also to investigate its effects on related symptoms such as fatigue and sleep disturbance.

This description comes directly from the study's public registry record.

Talk to the study team

Aleksandra Vuckovic, PhD  ·  +44 7906441955  ·  aleksandra.vuckovic@glasgow.ac.uk

Always discuss trial participation with your own doctor first.

Locations (1)

Clinical Research Facility (CRF), Queen Elizabeth University HospitalGlasgow, Scotland, United KingdomRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06240299